IMMUNITYBIO, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31)
IMMUNITYBIO, INC. (IBRX) reported Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) of $335.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses · last filed 2018-05-07
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $335.00K.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $220.00K.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $30.00K.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $12.00K.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for fiscal 2016 was $0.00.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss (deprecated 2018-01-31) for fiscal 2015 was $0.00.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) 9 month | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $335.00K 10-Q · filed 2018-05-07 | $555.00K derived: sum of 2 quarters · filed 2018-05-07 | $585.00K derived: sum of 3 quarters · filed 2018-05-07 | $597.00K derived: sum of 4 quarters · filed 2018-05-07 |
| 2017-12-31 | $220.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2018-05-07 | $250.00K derived: sum of 2 quarters · filed 2018-05-07 | $262.00K derived: sum of 3 quarters · filed 2018-05-07 | $262.00K 10-Q · filed 2018-05-07 |
| 2017-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $42.00K derived: sum of 2 quarters · filed 2017-11-07 | $42.00K 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $12.00K 10-Q · filed 2017-08-07 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-12 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |